Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-blind study of EVG/COBI/FTC/TAF vs EVG/COBI/FTC/TDF in treatment-naive adults with HIV-1 infection
jRCT2080222080Phase 3
- Sponsor
- Japan Tobacco
- Start
- May 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in human immunodeficiency virus infection (HIV) comparing EVG/COBI/FTC/TAF with EVG/COBI/FTC/TDF (2 arms).
02
Drugs
elvitegravir + cobicistat + emtricitabine + tenofovir alafenamideemtricitabine + elvitegravir + cobicistat + tenofovir disoproxil
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on jRCT2080222080.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080222080.